Affimed N.V.
AFMD - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.98M
Close$
$-4.20
2416.5% downside
Current Fair Value
2416.5% downsideOvervalued by 2416.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.98 Million |
|---|---|
| Enterprise Value | $9.08 Million |
| Earnings per Share | $-7.09 |
| Beta | 2.07 |
| Outstanding Shares | 16,100,185 |
Return
| Return on Equity | -406.92% |
|---|---|
| Return on Assets | -175.10% |
| Return on Invested Capital | -304.65% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.18 |
| Enterprise Value to Revenue | 10.35 |
| Enterprise Value to EBIT | -0.13 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.49 |
| Debt to Equity | 0.79 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 12, 2025
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.07%▼ 13.69% |
|---|---|
| Total Invested | $773▼ 99.95% |
| Investors Holding | 3▼ 26.00% |
About Affimed N.V.
76 employees
CEO: Shawn Leland
Affimed N.V. operates as a clinical-stage biopharmaceutical firm, dedicated to the discovery and advancement of immunotherapies targeting cancer across both the United States and Germany. Its primary therapeutic candidates include AFM13,...